KR 33028
Alternative Names: KR-33028Latest Information Update: 28 Feb 2023
At a glance
- Originator Yuyu
- Class Anti-ischaemics; Guanidines; Small molecules; Thiophenes
- Mechanism of Action Sodium-hydrogen antiporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ischaemic heart disorders
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Ischaemic-heart-disorders in South Korea (IV, Infusion)
- 02 Feb 2021 KR-33028 is still in preclinical trials for Ischaemic heart disorders in South Korea (Yuyu pipeline, February 2021)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Ischaemic-heart-disorders in South Korea (IV, Infusion)